Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Robert Bessler, a director at LifeStance Health Group, Inc. (NASDAQ:LFST), recently sold shares of the company, according to a filing with the Securities and Exchange Commission. The healthcare company, currently valued at $2.6 billion, has shown strong revenue growth of 18.5% over the last twelve months, according to InvestingPro data. On April 8 and April 9, Bessler sold a total of 4,914 shares, generating approximately $34,447. The shares were sold at prices ranging from $7.00 to $7.01 per share, slightly above the current trading price of $6.76. Following these transactions, Bessler holds a significant number of shares indirectly through entities such as Vitthal LLC and Shama LLC, with his direct holdings also remaining substantial. InvestingPro analysis suggests the stock is currently undervalued, with analyst targets ranging from $8 to $11 per share. Get access to the complete LifeStance Health Group Pro Research Report, along with detailed analysis of 1,400+ other US stocks, by subscribing to InvestingPro.
In other recent news, LifeStance Health Group reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of -$0.01 compared to the forecasted -$0.0383. The company also exceeded revenue forecasts, achieving $325.5 million against the anticipated $313.91 million. LifeStance Health demonstrated a 16% year-over-year revenue growth, reaching $325 million, and marked a milestone by achieving double-digit EBITDA margins for the first time. For the full year 2024, the company reported revenue of $1.251 billion, a 19% increase, and an adjusted EBITDA of $120 million, representing a 103% increase. Looking ahead, LifeStance Health projects 2025 revenue between $1.400 billion and $1.440 billion, with plans to open 25-30 new centers in 2025. In another recent development, KeyBanc Capital Markets initiated coverage on LifeStance Health with an Overweight rating, citing positive growth prospects. The firm highlighted the company's expected mid-teens organic top-line growth and margin expansion driven by increased clinician productivity and improved reimbursement rates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.